Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzamab

The anti-CD52 monoclonal antibody alemtuzumab is highly active in the treatment of chronic lymphocytic leukemia (CLL) in patients with previously treated, relapsed, and/or refractory CLL as well as in patients with previously untreated disease. The general immunosuppressive impact and toxicities associated with alemtuzumab therapy are largely predictable and manageable. In particular, cytomegalovirus (CMV) reactivation is now a well-documented complication in patients receiving alemtuzumab. This article discusses several strategies for monitoring and treating CMV reactivation in patients with CLL receiving alemtuzumab-based therapy and provides practical recommendations for CMV management by building upon the guidelines published previously in 2004.